Onderneming Sigilon Therapeutics, Inc.
Aandelen
SGTX
US82657L2060
Biotechnologie & Medisch Onderzoek
Vakgebied
Aantal werknemers: 62
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 60 | 14-08-18 | |
Director of Finance/CFO | 58 | 01-11-19 | |
Philip Johnson
PSD | President | 59 | 11-08-23 |
Bernd Kullmann
COO | Chief Operating Officer | - | - |
Qing Sarah Yuan
CTO | Chief Tech/Sci/R&D Officer | 53 | 07-03-22 |
Chief Tech/Sci/R&D Officer | 60 | 14-06-21 | |
Chief Administrative Officer | 52 | 01-01-19 | |
Michael Thompson
BRD | Director/Board Member | - | 11-08-23 |
Robert Windsor
IRC | Investor Relations Contact | - | 01-05-21 |
Chris Anderson
SEC | Corporate Secretary | - | 11-08-23 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 60 | 14-08-18 | |
Philip Johnson
PSD | President | 59 | 11-08-23 |
Gordon Brooks
BRD | Director/Board Member | - | 11-08-23 |
Michael Thompson
BRD | Director/Board Member | - | 11-08-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 2 502 084 | 2 294 190 ( 91,69 %) | 0 | 91,69 % |
Bedrijfsgegevens
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+21,39% | 47,9 mld. | |
+46,90% | 41,42 mld. | |
-2,47% | 40,7 mld. | |
-6,20% | 28,92 mld. | |
+9,71% | 25,55 mld. | |
-20,74% | 19,27 mld. | |
+0,23% | 12,15 mld. | |
+29,99% | 12,14 mld. | |
-0,51% | 11,99 mld. |